Evidence map›Paper›PMID 26261483›Full record

ArticleInternational journal of clinical and experimental pathology2015

Effect of antisense microRNA targeting survivin on rectal cancer HRC-9698 cells and its mechanism.

Jing Dai, Wei Wu, Jianyu Zhou, Kai Gao, Gui Hu, Changwei Lin, Yi Zhang, Xiaorong Li

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. MicroRNA: Another Pharmacological Avenue for Colorectal Cancer?Frontiers in cell and developmental biology · 2020
    Review
  2. Article
  3. MicroRNAs in colorectal carcinoma--from pathogenesis to therapy.Journal of experimental & clinical cancer research : CR · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jing DaiDepartment of General Surgery, The Third Xiang Ya Hospital of Central South University Changsha, Hunan 410013, P. R. China.
Wei WuDepartment of General Surgery, The Third Xiang Ya Hospital of Central South University Changsha, Hunan 410013, P. R. China.
Jianyu ZhouDepartment of General Surgery, The Third Xiang Ya Hospital of Central South University Changsha, Hunan 410013, P. R. China.
Kai GaoDepartment of General Surgery, The Third Xiang Ya Hospital of Central South University Changsha, Hunan 410013, P. R. China.
Gui HuDepartment of General Surgery, The Third Xiang Ya Hospital of Central South University Changsha, Hunan 410013, P. R. China.
Changwei LinDepartment of General Surgery, The Third Xiang Ya Hospital of Central South University Changsha, Hunan 410013, P. R. China.
Yi ZhangDepartment of General Surgery, The Third Xiang Ya Hospital of Central South University Changsha, Hunan 410013, P. R. China.
Xiaorong LiDepartment of General Surgery, The Third Xiang Ya Hospital of Central South University Changsha, Hunan 410013, P. R. China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRectal cancer seriously threats to human health. Traditional chemotherapy drugs might kill rectal cancer cells while easy cause side effects and clinical complications. Therefore, it is necessary to explore possible new methods for rectal cancer treatment. Survivin is an important tumor-specific protein. Previous researches showed it may be closely related to nasopharyngeal carcinoma. Its role in rectal cancer remains unclear.

methodsCultivate human rectal cancer HRC-9698 cells. Antisense microRNA targeting survivin and control miRNA were constructed and transfected to HRC-9698 cells. MTT assay was applied to detect cell growth. Flow cytometry was used to test cell apoptosis. Western blot was performed to detect Osteopontin expression level. Colony formation and transwell assay were used to test cell clone formation and invasion abilities.

resultsAntisense microRNA targeting survivin can inhibit HRC-9698 cell proliferation and induce its apoptosis. Antisense microRNA targeting survivin decreased osteopontin expression level. Overexpressed osteopontin inhibited antisense microRNA targeting survivin induced cell apoptosis. Antisense microRNA targeting survivin suppressed HRC-9698 cells' colony formation and invasion abilities.

conclusionAntisense microRNA targeting survivin induced osteopontin participated HRC-9698 cell apoptosis. Antisense microRNA targeting survivin inhibited HRC-9698 cell colony formation and invasive abilities, indicating that survivin may play its anti-tumor effect through inducing cell apoptosis and inhibiting cell metastasis and invasion.

Indexed as

ApoptosisCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticGenetic TherapyHumansInhibitor of Apoptosis ProteinsMicroRNAsNeoplasm InvasivenessOsteopontinRectal NeoplasmsRNA, AntisenseSurvivinTransfectionBIRC5 protein, humanInhibitor of Apoptosis ProteinsMicroRNAsOsteopontinRNA, AntisenseSPP1 protein, humanSurvivinapoptosisHRC-9698miRNAosteopontinproliferationsurvivin

Identifiers

PMID26261483
PMCPMC4525817
OpenAlexW1188305337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.